Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer

详细信息    查看全文

• 作者：Bunzo Nakata (1)
  Ryosuke Amano (1)
  Shigetomi Nakao (1)
  Tatsuro Tamura (1)
  Osamu Shinto (1)
  Toshiki Hirakawa (1)
  Yoshihiro Okita (1)
  Nobuya Yamada (1)
  Kosei Hirakawa (1)
  
• 刊名：Journal of Experimental & Clinical Cancer Research
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：29
• 期：1
• 全文大小：1632KB
• 参考文献：1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. / J Clin Oncol 2007, 25:1960鈥?966. CrossRef
  2. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. / Anti-Cancer Drugs 1996, 7:548鈥?57. CrossRef
  3. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. / Cancer Chemoth Pharm 2008, 61:615鈥?21. CrossRef
  4. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. / Br J Cancer 2005, 92:2134鈥?139. CrossRef
  5. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. / Oncology 2005, 69:421鈥?27. CrossRef
  6. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. / Br J Cancer 2006, 94:1575鈥?579.
  7. Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Makimoto A, Sato T: A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. / J Clin Oncol 2007., 25: Abst#4550
  8. Kim WY, Nakata B, Hirakawa K: Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and 伪-fluoro-尾-alanine after oral administration of S-1 following total gastrectomy. / Cancer Sci 2007, 98:1604鈥?608. CrossRef
  9. Chun YS, Ho JJL, Kim YS, Tanaka H, Nakata B, Hiura A, Motoyoshi H, Satake K, Umeyama K: The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. / Cancer 1987, 60:1636鈥?643. CrossRef
  10. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. / J Clin Oncol 1997, 15:2403鈥?413.
  11. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. / J Clin Oncol 1991, 9:491鈥?98.
  12. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kobayashi A, Tadenuma H, Ishiguro H, Saisho H: A phase II and pharmacokinetic trial of oral S-1 combined with gemcitabine (GEM) in patients with metastatic pancreatic cancer (MPC). / J Clin Oncol 2005., 23: Abst#4114
  13. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. / Br J Cancer 2003, 89:2207鈥?212. CrossRef
  14. Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, Hirao M, Furukawa H, Taguchi T: Phase I and Pharmacokinetic Study of S-1 Combined with Weekly Paclitaxel in Patients with Advanced Gastric Cancer. / Oncology 2005, 69:414鈥?20. CrossRef
  15. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G: Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. / Eur J Cancer 2003, 39:1547鈥?551. CrossRef
  16. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F: Relationship between fluorouracil systemic exposure and tumor response and patients survival. / J Clin Oncol 1994, 12:1291鈥?295.
  17. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S, Viola M: Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. / J Clin Oncol 2000, 18:3553鈥?557.
  18. Pressacco J, Mitrovski B, Erlichman C, Hedley DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. / Cancer Res 1995, 55:1505鈥?508.
  19. Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, Okami J, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. / Anticancer Res 2008, 28:179鈥?86.
  
• 作者单位：Bunzo Nakata (1)
  Ryosuke Amano (1)
  Shigetomi Nakao (1)
  Tatsuro Tamura (1)
  Osamu Shinto (1)
  Toshiki Hirakawa (1)
  Yoshihiro Okita (1)
  Nobuya Yamada (1)
  Kosei Hirakawa (1)
  
  1. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, 545-8585, Japan
  
• ISSN：1756-9966

文摘

Background The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer. Methods Six patients with advanced pancreatic cancer were enrolled in this pharmacokinetics (PK) study. These patients were treated by oral administration of S-1 30 mg/m2 twice daily for 28 consecutive days, followed by a 14-day rest period and intravenous administration of GEM 800 mg/m2 on days 1, 15 and 29 of each course. The PK parameters of GEM and/or 5-FU after GEM single-administration, S-1 single-administration, and co-administration of GEM with pre-administration of S-1 at 2-h intervals were analyzed. Results The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1. The Cmax, AUCinf, T1/2, and the time required to reach Cmax (Tmax) were not significantly different between S-1 administration with and without GEM. Conclusion There were no interactions between GEM and S-1 regarding plasma PK of GEM and 5-FU.